DISTINCTION BETWEEN BENIGN AND MALIGNANT TYPE OF PARKINSONS-DISEASE

被引:42
作者
BIRKMAYER, W
RIEDERER, P
YOUDIM, MBH
机构
[1] Ludwig Boltzmann Institute of Clinical Neurobiology, Lainz Hospital.
[2] Technion-Israel Institute of Technology, Faculty of Medicine, Department of Pharmacology Haifa
关键词
D O I
10.1016/0303-8467(79)90003-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clinical data demonstrate that there is a significant difference between at least two types of idiopathic Parkinsonian patients; a benign type of Parkinson's disease and a malignant type. They can be distinguished by the time course of a disability-score, independent of the duration of the disease. The benign cases respond very well to L-Dopa (Madopar) treatment and show a long lasting (7 years) drop in the disability, whereas the improvement of disability in the malignant cases is much smaller and lasts for about one year, followed by an increase of disability. The duration of the disease is 12,5 ± 0,4 years in the benign type but only 4,0 ± 0,3 years in the malignant type. Akinetic crises, off-phases, hyperkinetic crises and toxic deliria after Madopar treatment can be observed later in the benign than in the malignant cases. These results suggest that the degeneration of the dopaminergic nigrostriatal system occurs much more rapidly in malignant cases than in benign cases of Parkinson's disease. © 1979.
引用
收藏
页码:158 / 164
页数:7
相关论文
共 29 条
[1]  
Ambrozi, Birkmayer, Danielczyk, Neumayer, Riederer, Biochemische Aspekte des menschlichen Verhaltens, Wr. Z. Nervenheilk., 31, (1973)
[2]  
Ambrozi, Birkmayer, Riederer, Youdim, L-Dopa and (−) Deprenyl in the treatment of Parkinson's disease, Brit. J. Pharmacol., 58, 3, (1976)
[3]  
Barbeau, Advanc. Neurology, Treatment of Parkinson's disease with L-Dopa and R04-4602
[4]  
review and present status, 2, (1973)
[5]  
Bartholini, Prada, Pletscher, Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase, J. Pharm. Pharmacol., 20, (1968)
[6]  
Bernheimer, Birkmayer, Hornykiewicz, Jellinger, Seitelberger, Brain dopamine and the syndromes of Parkinson and Huntington, J. Neurol. Sci., 20, (1973)
[7]  
Birkmayer, Mentasti, Weitere experimentelle Untersuchungen über den Catechol-aminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson und Chorea-Syndrom), Arch. Psychiat. Nervenkr., 210, (1967)
[8]  
Birkmayer, Neumayer, Die moderne medikamentöse Behandlung des Parkinsonismus, Z. Neurol., 202, (1972)
[9]  
Birkmayer, Neumayer, Die Behandlung der Dopa-Psychosen mit L-Tryptophan, Nervenarzt, 43, (1972)
[10]  
Birkmayer, Danielczyk, Neumayer, Riederer, L-Dopa level in plasma, primary condition for the kinetic effect, J. Neural Transm., 34, (1973)